Biosimilars – Emerging Biosimilars – Oncology: Zarxio Launch Tracking (US) Wave 1

x

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology: Zarxio Launch Tracking (US) Wave 1
    • Key Findings
      • Unaided Awareness of Zarxio Is Low
      • The Majority of Surveyed Oncologists Are Yet to See a Zarxio Medical Representative
      • Who Is the Zarxio Patient?
        • Patient Age
        • Drug Benefit Coverage
        • Primary Treatment
        • Use in G-CSF-Nau00efve / Currently Treated Patients
      • Who Is the Zarxio Prescriber?
        • Level of Satisfaction with Zarxio
        • Recommendations/Pressure to Use Zarxio
        • Perception of Zarxio's Net Cost
        • Preference for Short-/Long-Acting G-CSF
      • Trends & G-CSF Market
        • Trends Regarding the Uptake of Zarxio
        • Zarxio's Place in the G-CSF Market
      • Zarxio: Differences Between Prescriber and Nonprescriber Profiles
      • Formulary Analysis
        • Reimbursement of G-CSFs
        • Commercial Coverage of G-CSFs in the United States
        • Explanation of Tiers and Restrictions
        • Tier Placement of G-CSFs - Commercial
        • National Tier Placement of G-CSFs by Percentage of Lives: Commercial
        • Tier Placement of G-CSFs - Medicare
        • National Tier Placement of G-CSFs by Percentage of Lives: Medicare
        • Any Formulary Restrictions on G-CSFs
        • Any Formulary Restrictions on G-CSFs: Commercial
        • Any Formulary Restrictions on G-CSFs: Medicare
        • Prior Authorization for G-CSFs
        • Prior Authorization Formulary Restrictions on G-CSFs: Commercial
        • Prior Authorization Formulary Restrictions on G-CSFs: Medicare
        • Quantity Limits on G-CSFs
        • Quantity Limit Formulary Restrictions on G-CSFs: Commercial
        • Quantity Limit Formulary Restrictions on G-CSFs: Medicare
      • Zarxio Awareness and Perceptions
        • Unaided Awareness of Zarxio
          • Unaided Awareness of Biologics Approved for Chemotherapy-Induced Neutropenia
          • Chemotherapy-Induced Neutropenia Biologics Recalled
          • Order Biologics for Chemotherapy-Induced Neutropenia Are Recalled
          • Order of Biologics Recalled for Chemotherapy-Induced Neutropenia
        • Level of Familiarity with Biosimilars and Zarxio
          • Level of Familiarity
        • Physician Perception of Indications in Which Zarxio Was Studied
          • Indications in Which Physicians Believe Zarxio Was Clinically Studied Prior to Approval
        • Physician Perception of Zarxiou2019s Approved Indications
          • Indications Physicians Believe Zarxio is Approved to Treat
        • Information on Zarxiou2019s Development
          • Physician Perception of Indications Zarxio Should Be Approved to Treat
            • Indications Physicians Believe Zarxio Should Be Approved to Treat
        • Zarxio Trial and Use
          • Patients Prescribed Zarxio
            • Prescription of Zarxio: Patients Receiving Myelosuppressive Chemotherapy
            • Oncologists Prescribing Zarxio to Cancer Patients Receiving Myelosuppressive Chemotherapy
            • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Prescribed Zarxio
            • Prescription of Zarxio: Other Hematology-Oncology Patients
            • Hematology-Oncologists Prescribing Zarxio to Patients
            • Number of Hematology-Oncology Patients Prescribed Zarxio
            • Prescription of Zarxio: Any Indication
            • Proportion of Oncologists That Has Prescribed Zarxio to at Least One Patient
            • Healthcare Coverage of Zarxio-Treated Patients
            • Healthcare Coverage for Patients Treated with Zarxio
            • Prevalence of Treatment Switching to Zarxio or Use of Zarxio in Treatment-Nau00efve Patients
            • Proportion of Zarxio-Treated Patients Who Were G-CSF-Nau00efve or Switched from Another G-CSF
            • Current and Future Patient Share of G-CSF Products
            • Current and Future Patient Share Assuming Pegfilgrastim Biosimilars Are Not Available
            • Patient Share Expectations Among Zarxio Prescribers and Nonprescribers
            • Current and Future Patient Share of Long- and Short-Acting G-CSFs
          • Prescribers' Experience of Zarxio
            • Reasons for Prescribing Zarxio
            • Reasons for Choosing to Prescribe Zarxio
            • Perceived Similarity Between Zarxio and Neupogen
            • Oncologists' Perception of Zarxiou2019s Similarity to Neupogen
            • Reported Differences Between Zarxio and Neupogen
            • Satisfaction with Zarxio
            • Overall Level of Satisfaction with Zarxio
            • Perceived Cost of Zarxio
            • Perceived Discount of Zarxio Compared with Neupogen Net Cost
            • Filgrastim Pricing and Medicare Part B Reimbursement
            • Pricing and Medicare Part B Payment Limit/1 mcg of Filgrastim Products
          • Reasons for Not Prescribing Zarxio
            • Oncologists' Reasons for Not Prescribing Zarxio
            • Reasons for Granix Preference
            • Reasons for Oncologists' Preference for Granix over Zarxio
        • External Factors Affecting Zarxio Use
          • Factors That Could Increase Use of Zarxio
          • Factors That Would Encourage Use or Increase Use of Zarxio
          • Sources of Pressure or Recommendations for Use of Zarxio
          • Sources of Pressure for the Use of Zarxio Instead of Other G-CSF Brands
          • Predicted Uptake of Zarxio
          • Predicted Variability in Zarxio Uptake Depending on Patientsu2019 Healthcare Coverage
          • Rate of Acceptance of Zarxio by Patients
          • Percentage of Patients Who Accepted Zarxio When Proposed
          • Opinions on Nonproprietary Names for Biosimilars
          • Oncologists' Opinions on Nonproprietary Names for Biosimilars
        • G-CSF Promotional Activity
          • Most Recent Contact with Medical Representatives
          • Most Recent Contact with Medical Sales Reps for Zarxio and Competitors
          • Topics of Discussion with Medical Representatives
          • Topics Discussed with Medical Representative
        • Future Use of Biosimilars
          • Zarxio's Influence on Willingness to Use Other Biosimilars
            • Likelihood of Prescribing Other Biosimilars: Medical Oncologists
            • Likelihood of Prescribing Other Biosimilars of Oncology Brands as a Result of Zarxio Use
            • Likelihood of Prescribing Other Biosimilars: Hematology-Oncologists
            • Likelihood of Prescribing Biosimilars of Other Products as a Result of Zarxio Use
          • Likelihood of Prescribing Different Filgrastim Biosimilars
          • Likelihood of Prescribing Other Filgrastim Biosimilars
          • Future Patient Share With or Without Pegfilgrastim Biosimilars
          • Future Patient Share if Pegfilgrastim Biosimilars Are Available at a 15-30% Discount to Neulasta
        • Appendix
          • Background on the US G-CSF Market
            • US G-CSF Market Background
            • Short-acting G-CSFs
            • Short-acting G-CSFs
            • Short-Acting G-CSFs US Market Share
            • Long-Acting G-CSFs
            • Approved Long-Acting G-CSFs
            • Long-Acting G-CSF US Market Share
            • G-CSFs Approved in the United States
            • G-CSF Market News
            • Zarxio's Route to the US Market
            • Zarxio's Future Competitive Landscape in the United States
          • Methodology and Objectives
            • Methodology
            • Objectives
            • Significance Testing in This Study
            • Significance Testing in This Study
          • Respondent Demographics
            • Practice Location
            • Practice Location
            • Regional Location of Oncologists
            • Distribution of Oncologists by Region
            • Years in Clinical Practice and Practice Type
            • Years in Clinical Practice
            • Practice Type
            • Patients Under Management: Medical Oncologists
            • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Managed Per Month
            • Patients Under Management: Hematology-Oncologists
            • Number of Cancer Patients Under Management Per Month
            • Drug Benefit Coverage for Neutropenia Patients
            • Drug Benefit Coverage
            • Drugs Prescribed by Medical Oncologists
            • Drugs Prescribed by Medical Oncologists
            • Drugs Prescribed by Hematology-Oncologists
            • Drugs Prescribed by Hematology-Oncologists